Carmine Zoccali & Francesca Mallamaci comment on: #Empagliflozin in chronic #kidney disease: evidence for early, inclusive, and confident use thelancet.com/journals/landi… #SGLT2 inhibitor #CKD #FREE to read with registration (also FREE)

Almost all u need 2 know about the remarkable clinical effects of #SGLT2i on the kidney in a wide ranging IPD metaanalysis (covers effects by albuminuria, predicted eGFR dip and novel exploratory eGFR slope methods). Please do read it! Oxford Population Health (OxPop) Natalie Staplin Martin Landray

Celebrating our newest full-fledged DPhil candidate Dilushi Wijayaratne

A drop in Uromodulin might partly explain the nephroprotective effects of SGLT-2 I Greco Mark Malijan Natalie Staplin Will Herrington Oxford Population Health (OxPop) markusathome ajkd.org/article/S0272-…

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy (OPEN ACCESS) Greco Mark Malijan Natalie Staplin Dilushi Wijayaratne Killian Donovan Doreen Zhu Michaela Petrini Sarah Ng Katherine Tuttle Martin Landray Christoph Wanner Michael Shlipak

If you’re at #KidneyWk today, do join the poster sessions! I’ll be sharing our work on the effects of #SGLT2i and neprilysin inhibition on urine biomarkers in EMPA-KIDNEY and UK HARP-III, respectively. Will be there at 10-12, posters 1169-1170.

Meta-analysis: #SGLT2 inhibitors slow kidney decline consistently across CKD severity and albuminuria range, supporting their routine use for kidney health. 🧵 #KidneyWK American Society of Nephrology ja.ma/4oniolr

Michaelmas term so far! Blink and you’ll miss it.

Review by Anthony Bleyer et al: Autosomal Dominant Tubulointerstitial Kidney Disease: A Review bit.ly/3VgPMNS (FREE)

Final call for the Oxford-GSK Clinical DPhil programme, open to clinical trainees at ST4 or above, deadline 2nd Dec Medical Sciences Nuffield Department of Medicine OUH #OUCAGS Renal SpR Club Association of British Neurologists medsci.ox.ac.uk/study/graduate…

Cell–cell crosstalk in kidney health and disease nature.com/articles/s4158…

2025 @thelancet.com #CKD seminar out! Read it for the latest evidence on how to manage what is projected to become a top 5 leading cause of death globally by 2050 (read it so in 25years’ time that does not happen…): sciencedirect.com/science/articl…

We’re delighted the Government is extending the #RareDiseasesFramework for another year. Our recent report ‘Collectively common: the devastating impact of rare kidney diseases in the UK’ found there are an estimated 160,000 people living with a #RareKidneyDisease in the UK. Many

Pathogenesis of podocytopathies brilliantly elucidated at GlomCon fellowship by Paola Romagnani Demand, reserve and regeneration

End of Michaelmas Term and completed DPhil confirmation. After all these years the magic is still there. I still can’t believe I get to do what I do in a place like #Oxford. Truly I’m so lucky.

Fascinating Effects of Empagliflozin on UMOD in EMPA-KIDNEY - American Journal of Kidney Diseases - discussed ⁦Taiwan Society of Nephrology (TSN)⁩ yesterday #APCNxTSN25 ⁦Greco Mark Malijan⁩ DPhil ajkd.org/article/S0272-…

#EASi-KIDNEY’s December logo🎄🎅 . ‘Tis the season to be jolly!! ⁦Oxford Population Health (OxPop)⁩

Ten tips on performing economic evaluation in kidney disease doi.org/10.1093/ckj/sf…

First of the series of bakes this month! (We hope to take care of #kidneys in all shapes and forms.)

How much #uromodulin is in this #kidney?